Dr Alva is a board-certified psychiatrist, a paid consultant of Otsuka America Pharmaceutical, Inc, and Lundbeck, and Mood Disorders Section Editor for Psychiatric Times.
Current Challenges With MDD Treatment Options
January 26th 2023Carmen Kosicek, MSN, PMHNP-BC, leads a discussion on the level of satisfaction for both patients and providers with currently available MDD treatment options, barriers to access, and the impact of residual symptoms on a patient’s quality of life.
Role of Telemedicine in Bipolar Disorder
Michael E. Thase, MD; Theresa Cerulli, MD; Gustavo Alva, MD, DFAPA; and Tina Matthews-Hayes, DNP, FNP, PMHNP, provide insight on the role of telemedicine in improving outcomes for patients with bipolar disorder.
Patient Case #2 Continued: Novel Second-Generation Antipsychotics
A panel of experts in psychiatry consider the use of a novel second-generation antipsychotic for the management of treatment resistant depression.
Theresa Cerulli, MD, and Tina Matthew-Hayes, DNP, FNP, PMHNP, review diagnostic difficulties of the patient’s primary care physician in patient case #1 and share optimal approaches to the diagnosis and treatment for patients with bipolar disorder.
Clinical Impressions From Patient Case #1
Tina Matthews-Hayes, DNP, FNP, PMHNP, comments on screening tools for bipolar disorder and Gustavo Alva, MD, DFAPA, shares his impressions from patient case #1.